文献速递癫痫

颅内神经调控治疗耐药性癫痫的安全性:儿童与成人单中心回顾性研究

Safety of Intracranial Neuromodulation in Drug-Resistant Pediatric and Adult Epilepsy.
PubMed 文献 · Neurology · 2026-01-23

总体不良事件可接受,但女性装置取出率显著高于男性,儿童和4导联DBS患者弓弦效应风险更高。

要点

  • 颅内神经调控在儿童和成人耐药性癫痫中总体安全性可接受。
  • 女性装置取出率显著高于男性(11.9% vs 1.9%,p=0.006)。
  • 儿童和4导联DBS患者弓弦效应风险更高,需定制装置与手术策略。

核心结论

  • 颅内神经调控在性别和年龄组中显示可接受的安全性,但儿童和4导联DBS系统患者弓弦效应风险增加。

主要发现

  • 装置相关不良事件包括刺激相关感觉异常7.8%、感染4.1%、无症状颅内出血3.7%、弓弦效应3.2%、手术相关局灶无力2.3%、伤口裂开1.8%、装置移位1.8%、电极位置异常1.4%、电极断裂1.4%、电极移位0.5%、延伸导线断裂0.5%、挤出0.5%、症状性颅内出血0.5%。
  • 女性装置取出率显著高于男性(11.9% [13/109] vs 1.9% [2/108],p=0.006)。
  • 儿童和4导联DBS患者与其他年龄组和装置类型相比,弓弦效应风险更高。

临床怎么用

  • 临床实践中应关注女性患者装置取出的风险,并针对儿童和4导联DBS患者优化装置设计与手术策略以降低弓弦效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Intracranial neuromodulation is an established therapy for drug-resistant epilepsy (DRE) in adults. Improving seizure outcomes and expanding its application to pediatric patients remain priorities. Off-label use of 2-lead and 4-lead devices targeting multiple network nodes, combined with varied stimulation parameters, has emerged in pursuit of better outcomes. Although early findings are promising, the safety of these approaches remains underexplored. This study evaluates adverse event (AE) rates associated with different intracranial neuromodulation devices from a single center. METHODS: This retrospective study from the Mayo Clinic (Rochester, MN) included patients with DRE who underwent intracranial neuromodulation between August 2004 and December 2024. Demographic data, epilepsy characteristics, treatment indications, procedural details, and AEs were extracted from medical records. AEs are undesirable events associated with implantation and use of the device, regardless of causation. Serious AEs were life threatening or resulted in hospitalization, persistent or significant disability, or death. Patients were classified as children (<13 years), adolescents (13-18 years), or adults (≥19 years). RESULTS: A total of 217 patients (108 male patients, 109 female patients; 14 children, 43 adolescents, 160 adults) were analyzed. Devices included 2-lead deep brain stimulation (DBS) (111 patients), 4-lead DBS (51 patients), and responsive neurostimulation (55 patients). Device-related AEs included stimulation-related paresthesia (7.8%), infections (4.1%), asymptomatic intracranial hemorrhage (ICH) (3.7%), bowstring effect (extension wire tethering that limits neck mobility) (3.2%), operation-related focal weakness (2.3%), wound dehiscence (1.8%), device migration (1.8%), lead malposition (1.4%), lead fracture (1.4%), lead migration (0.5%), extensor wire fracture (0.5%), extrusion (0.5%), and symptomatic ICH (0.5%). While no significant difference in overall AE rates was found between sexes, device explantation was significantly higher in female patients than in male patients (11.9% [13/109] vs 1.9% [2/108], p = 0.006). Children and patients with 4-lead DBS had a higher risk of developing bowstringing compared with other age groups and device types. DISCUSSION: Intracranial neuromodulation demonstrated an acceptable safety profile across sexes and age groups. However, children and patients with 4-lead DBS systems were at increased risk of the bowstring effect. These findings highlight the need for tailored device design and surgical strategies to optimize safety, particularly in pediatric populations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kuo CY, Mivalt F, Singh R, et al. Safety of Intracranial Neuromodulation in Drug-Resistant Pediatric and Adult Epilepsy. Neurology. 2026. PMID: 41576312. doi:10.1212/WNL.0000000000214626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。